Clinical Trial Update: New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 trial evaluating the new combination inhaler FlutiForm HFA MDI for asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm HFA MDI 100/10 µg and 250/10 µg (fluticasone propionate/formoterol)

Snippet

Sponsor: SkyePharma AG | Conditions: Asthma | Phase 3 | Status: COMPLETED